AZURE all patients |
3 360 |
stage II/III |
95 % |
zoledronate 4 mg, 6 × q3-4w, 8 × q3m, 5 × q6m |
60 m |
0.98 (p = 0.79) |
1.01 (p = 0.93) |
Coleman, 2011 42
|
AZURE postmenopausal patients |
1 101 |
stage II/III postmenopausal |
95 % |
zoledronate 4 mg, 6 × q3-4w, 8 × q3m, 5 × q6m |
60 m |
0.71 (p = 0.0017) |
0.71 (p = 0.017) |
Coleman, 2011 42
|
ABCSG-12 |
1 803 |
premenopausal |
< 5 % |
zoledronate 4 mg, 6 × q6m |
84 m |
0.72 (p = 0.014) |
0.63 (p = 0.0049) |
Gnant, 2009 41
|
ZOFAST |
1 065 |
postmenopausal |
0 % |
zoledronate 4 mg, 6 × q6m |
60 m |
0.66 (p = 0.0375) |
n. s. |
de Boer, 2011 28
|
NSABP-B34 |
3 323 |
all stages |
65 % |
clodronate 1 600 mg/d over 5 years |
101 m |
0.91 (p = 0.27) |
0.84 (p = 0.13) |
Paterson, 2011 32
|
Powles |
1 069 |
all stages |
? |
clodronate 1 600 mg/d over 2 years |
88 m |
0.77 (p = 0.127) |
0.77 (p = 0.047) |
Powles, 2002 44
|
Diel |
302 |
DTC in KM |
40 % |
clodronate 1 600 mg/d over 2 years |
103 m |
0.98 (p = 0.222) |
0.83 (p = 0.049) |
Diel, 2008 43
|
Sarto |
296 |
nodal positive |
90 % |
clodronate 1 600 mg/d over 2 years |
98 m |
n. s. |
n. s. |
|